Opthea Developing Therapy for Eye Diseases

Opthea is a public Australian biotechnology company (ASX:OPT) developing a novel biologic therapy, OPT-302, for the treatment of eye diseases.

OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and   VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 in wet AMD patients. 

Opthea is currently enrolling patients in a Phase 2b clinical trial for patients with wet AMD and a Phase 1b/2a clinical trial in patients with DME.  

Latest News

08 NOV 2018. “Opthea hosts KOL Forum in New York City: Beyond anti-VEGF-A for Retinal Diseases"


“Beyond anti-VEGF-A for Retinal Diseases"

listen to the presentation >>

26 OCT 2018. “Opthea CEO Presents Trial Updates including Positive Data from Ph1b DME Study of OPT-302 at Ophthalmology Innovation Summit"


26 OCT 2018. “Opthea Reports Positive Data from Ph1b DME Study of OPT-302"


03 JAN 2018. “Opthea Initiates OPT-302 Diabetic Macular Edema Trial"


19 DEC 2017. “Opthea Doses First Patient in OPT-302 wAMD Ph2b trial"

Share Price